tiprankstipranks

Argenx upgraded to Outperform from Market Perform at Bernstein

Bernstein analyst Justin Smith upgraded Argenx (ARGX) to Outperform from Market Perform with a EUR 755 price target The firm is increasing its 2030 group sales forecast by over 100% to $11B, which implies that key growth driver Vyvgart will become the 4th largest autoimmune drug ever. But this new 2030 risk adjusted group sales estimate equates to 30k treated patients for a share of 6%. Bernstein says its analysis also suggests that the risks to the s/p are strongly skewed to the upside.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue